res m glp 1 reviews GIPR/GLP-1R dual agonist therapies for diabetes and weight loss—chemistry, physiology, and clinical applications GLP-1 agonists and changes in

Updated June 2026 Medically reviewed by Dr

If you do not experience an immediate reduction in your appetite, do not feel discouraged or assume the treatment is failing

Tirzepatide (Zepbound): The Dual-Action Powerhouse Tirzepatide's dual-agonist action on both GLP-1 and GIP receptors is what makes it so compelling, often delivering slightly superior weight loss results in clinical trials

From cardiovascular and neurodegenerative diseases to chronic kidney disease, osteoarthritis, liver health, sleep apnea, addiction, and fertility issues, these medications offer new hope for managing complex health conditions and improving patient lives

Available from: UpToDate Lexi-Drugs

Incorporating light Zone 2 aerobic activities like walking, biking, or low-impact cardio can help circulation, mood, and long-term weight maintenance